By Connor Hart
Adobe's fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion that analysts polled by FactSet expect. It also guided for adjusted per-share earnings between $20.20 and $20.50, compared with the $20.52 for which analysts are looking. The company's lower-than-expected outlook came as it posted higher revenue and earnings in its fiscal 4Q. Shares slide 8.8%, to $501.55, in after-hours trading.
Champions Oncology swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements. The technology-enabled research company posted earnings of 5 cents a share on revenue of $13.5 million, compared with a loss of 15 cents a share on revenue of $11.6 million a year earlier. Chief Executive Ronnie Morris said the company is cautiously optimistic that the pharma and biotech environments are improving. Shares jump 13%, to $6.59, in postmarket trading.
DBV Technologies confirmed alignment with the Food and Drug Administration on an accelerated approval for its Viaskin Peanut Patch in children aged 1 to 3. The biopharmaceutical company said it aligned with the FDA on key study design elements for its Comfort Toddlers study, including study size, wear time collection methodology and analysis. It expects to submit a biologics license application for the toddlers' indication of the Viaskin Peanut Patch in the second half of 2026. Shares surge 28%, to $4.20, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 11, 2024 18:40 ET (23:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。